Medannex’s First-in-class Therapy receives EMA Orphan Designation for Pancreatic Cancer
Medannex’s First-in-class Therapy receives EMA Orphan Designation for Pancreatic Cancer Medannex Ltd (Edinburgh) announced today that MDX-124, a monoclonal antibody against annexin-A1, has received Orphan Medicinal Product positive opinion from the European Medicines Agency (EMA) for the treatment of pancreatic...